Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia



Status:Completed
Conditions:Cancer, Other Indications, Blood Cancer, Blood Cancer, Psychiatric, Hematology, Leukemia
Therapuetic Areas:Hematology, Oncology, Psychiatry / Psychology, Other
Healthy:No
Age Range:18 - 120
Updated:1/20/2017
Start Date:February 2006
End Date:October 2008

Use our guide to learn which trials are right for you!

Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study

RATIONALE: Supportive care, such as healing touch, may improve quality of life in patients
receiving chemotherapy for acute leukemia.

PURPOSE: This clinical trial is studying how well healing touch works in treating patients
receiving chemotherapy for acute myeloid leukemia or acute lymphocytic leukemia.

OBJECTIVES:

- Determine the feasibility of conducting a randomized controlled trial, in terms of
recruiting and retaining participants, to a study of healing touch (HT) as supportive
care in patients receiving chemotherapy for acute myeloid leukemia or acute
lymphoblastic leukemia.

- Examine potential barriers to participation and ascertain reasons for study drop-outs
in these patients.

- Demonstrate whether these patients will comply with treatment sessions and remain in
the study.

- Obtain preliminary data on the effectiveness of HT on psychological distress and
treatment-related symptoms focusing on fatigue and sleep disturbances in these
patients.

- Determine if the HT protocol needs to be refined, modified, or eliminated, based on
pilot participant feedback, for a randomized clinical trial.

OUTLINE: This is a pilot study.

Within 1 week of admission to the hospital, patients are interviewed by a research assistant
about previous use of complementary or alternative medicine therapies, knowledge of healing
touch (HT), previous experience with HT, willingness to participate in a study of HT for
acute leukemia patients, and willingness to be randomized in a HT study. The first 12
patients interested in undergoing HT undergo a 30-minute session of HT therapy 3 times a
week during weeks 2, 3, and 4 of induction or reinduction chemotherapy. Patients are also
asked to rate current distress, pain, fatigue, and nausea before and after the second HT
session during weeks 2, 3, and 4. Patients also complete self-report questionnaires at
baseline, during week 5 of induction or reinduction chemotherapy or prior to discharge from
the hospital, and during the first week of consolidation chemotherapy (approximately week
9-13).

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

- Diagnosis of one of the following acute leukemias:

- Acute lymphocytic leukemia

- Acute myeloid leukemia

- Hospitalized for induction (newly diagnosed patients) or reinduction (relapsed
patients) chemotherapy

- Must be oncology inpatients at Wake Forest University Baptist Medical Center

PATIENT CHARACTERISTICS:

- Must know adequate English to understand the consent form, complete questionnaires,
and converse with study staff

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics
We found this trial at
1
site
1 Medical Center Blvd
Winston-Salem, North Carolina 27103
(336) 716-2011
Wake Forest University Comprehensive Cancer Center Our newly expanded Comprehensive Cancer Center is the region’s...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials